Ending apathy in an age of tuberculosis drug resistance

A primary focus on AIDS and lack of access to cheap life-saving medication has left the world potentially facing an epidemic of virtually untreatable tuberculosis (TB), an ANU academic has warned.

Senior Research Fellow at thSenior Research Fellow at the University’s Centre for Applied Philosophy and Public Ethics, Dr Michael Selgelid is warning on World TB Day (March 24) that more needs to be done to stop the spread of TB – a disease that still kills 1.7 million people each year.

Dr Selgelid said that it was a disgrace that more than 50 years after a cure for TB was found, the disease should still cause such a large death toll around the world.

“The global TB status quo is shameful,” said Dr Selgelid. “Though cures have existed since the 1950s, TB is still the second leading infectious cause of mortality – a close runner up to AIDS. One third of the world population is infected with latent TB and 10 per cent of these are expected to develop active illness at some time in their lives.”

The threat of TB has increased significantly in the last 20 years, first through the detection of Multi-Drug Resistance (MDR) TB and recently through ‘Extreme’ or ‘Extensively’ Drug-Resistant (XDR) TB. XDR-TB, said Dr Selgelid, has been found in 45 countries and every region of the world.

“Because XDR-TB is virtually untreatable we have returned to a situation analogous to the pre-antibiotic era. This has occurred for a number of reasons, including that not enough people in developing countries could afford to complete their treatment.

“It’s astonishing that TB has largely escaped the attention of bioethicists. A medical literature database search found 2998 publications addressing AIDS, but only 179 addressing TB and ethics. But while AIDS has been highly politicised, TB has primarily affected the poor so there hasn’t been as much advocacy of TB control in the rich countries where most bioethicists work.”

He added that with World TB Day approaching and the threat of XDR-TB, renewed efforts needed to be made to address the problem.

“XDR-TB should be a wake-up call and galvanise policy makers worldwide. Developed countries must do more to improve health care in developing countries. In addition to the moral imperative to easing the untold suffering and millions of unnecessary deaths, there are straightforward self-interested reasons – bad health in poor countries jeopardises the health of populations in Australia and other rich countries.

“World TB Day should remind us that it’s high time to stop TB – it could and should have been stopped long ago.”

e University’s Centre for Applied Philosophy and Public Ethics, Dr Michael Selgelid is warning on World TB Day (March 24) that more needs to be done to stop the spread of TB – a disease that still kills 1.7 million people each year.

Dr Selgelid said that it was a disgrace that more than 50 years after a cure for TB was found, the disease should still cause such a large death toll around the world.

“The global TB status quo is shameful,” said Dr Selgelid. “Though cures have existed since the 1950s, TB is still the second leading infectious cause of mortality – a close runner up to AIDS. One third of the world population is infected with latent TB and 10 per cent of these are expected to develop active illness at some time in their lives.”

The threat of TB has increased significantly in the last 20 years, first through the detection of Multi-Drug Resistance (MDR) TB and recently through ‘Extreme’ or ‘Extensively’ Drug-Resistant (XDR) TB. XDR-TB, said Dr Selgelid, has been found in 45 countries and every region of the world.

“Because XDR-TB is virtually untreatable we have returned to a situation analogous to the pre-antibiotic era. This has occurred for a number of reasons, including that not enough people in developing countries could afford to complete their treatment.

“It’s astonishing that TB has largely escaped the attention of bioethicists. A medical literature database search found 2998 publications addressing AIDS, but only 179 addressing TB and ethics. But while AIDS has been highly politicised, TB has primarily affected the poor so there hasn’t been as much advocacy of TB control in the rich countries where most bioethicists work.”

He added that with World TB Day approaching and the threat of XDR-TB, renewed efforts needed to be made to address the problem.

“XDR-TB should be a wake-up call and galvanise policy makers worldwide. Developed countries must do more to improve health care in developing countries. In addition to the moral imperative to easing the untold suffering and millions of unnecessary deaths, there are straightforward self-interested reasons – bad health in poor countries jeopardises the health of populations in Australia and other rich countries.

“World TB Day should remind us that it’s high time to stop TB – it could and should have been stopped long ago.”

Source: ANU

Related stories:

Antiretroviral therapy as HIV prevention strategy
The widespread use of highly active antiretroviral therapy may reduce the incidence of HIV in individuals and populations but has been overlooked by public health as a prevention strategy, write Dr. Julio Montaner and colleagues in Canadian Medical Association Journal.
Senate reaches an agreement on global AIDS bill
(AP) -- Senate negotiators said Wednesday they had reached a tentative agreement on a key obstacle to one of the most ambitious federal health initiatives ever, a $50 billion act to combat AIDS, malaria and tuberculosis in Africa and other countries hard-hit by those diseases.
Internet, tolerance spark change in urban gay communities
Gay communities – such as clubs, bars, events and neighborhoods – appear to be changing worldwide in light of several key factors, including Internet dating and achievement of civil rights, according to new University of Minnesota research.
'Blood-free' monitoring as good as blood tests in predicting the course of AIDS
Researchers at the University of Pennsylvania School of Medicine have shown that monitoring treatment adherence to AIDS therapy is a simple blood-free way to monitor risk of disease progression. The international study was published in the May issue of the journal PLoS Medicine.
Major shift in HIV prevention priorities needed
According to a new policy analysis led by researchers at the Harvard School of Public Health (HSPH) and the University of California, Berkeley, the most common HIV prevention strategies—condom promotion, HIV testing, treatment of other sexually transmitted infections (STIs), vaccine and microbicide research, and abstinence—are having a limited impact on the predominantly heterosexual epidemics found in Africa. Furthermore, some of the assumptions underlying such strategies—such as poverty or war being major causes of AIDS in Africa—are unsupported by rigorous scientific evidence.
NIAID describes research priorities to fight drug-resistant tuberculosis
Tuberculosis (TB) has long been one of the world’s great killers. Now, forms of drug-resistant TB--multidrug (MDR) and extensively drug-resistant (XDR)--are occurring at an ominous and accelerating rate. To help in the fight against drug-resistant TB, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has formulated an MDR and XDR TB research agenda.
Life expectancy no longer improving for large segment of the US population
One of the major aims of the U.S. health system is improving the health of all people, particularly those segments of the population at greater risk of health disparities. In fact, overall life expectancy in the U.S. increased more than seven years for men and more than six years for women between 1960 and 2000.
Research identifies first method for testing, assessing drug treatments for Chagas' disease
Chagas’ disease is a tropical parasitic sickness that currently affects more than 16 million people, with a staggering 100 million at risk, largely in the tropical areas of South and Central America. And yet the main drug used to treat the disease is highly toxic and causes serious side effects.

News discussion:

Medicine & Health news